TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06449001: A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis

Sponsor: Alexion Pharmaceuticals, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,485,920

Rescue Site Savings

+$5,610,136

Unlock Full NCT06449001 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06449001 Rescue Dossier →